Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Daily News

Fracking, Other Natural Gas Activity Linked to Hospitalizations for HF Patients

L.A. McKeown

December 07, 2020

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

News Industry News

Corvia Medical Completes Randomization In Reduce Lap-Hf II Pivotal Trial And Gains Fda Authorization To Provide Continued Access For The Corvia Atrial Shunt

November 17, 2020

News Daily News

Heart Failure Doubles Risk of Dying From COVID-19

L.A. McKeown

October 30, 2020

News Conference News HFSA 2020

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

L.A. McKeown

October 12, 2020

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

L.A. McKeown

October 09, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2020

Shelley Wood

October 01, 2020

News Daily News

Recurrent Events After MI Show Enduring Gender, Racial Gaps in Care

Shelley Wood

September 22, 2020

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

Todd Neale

August 30, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Daily News

Stick-on Sensor Predicts Heart-Failure Hospitalizations: Pilot Study

Shelley Wood

February 26, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Advertisement

Fracking, Other Natural Gas Activity Linked to Hospitalizations for HF Patients

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Corvia Medical Completes Randomization In Reduce Lap-Hf II Pivotal Trial And Gains Fda Authorization To Provide Continued Access For The Corvia Atrial Shunt

Heart Failure Doubles Risk of Dying From COVID-19

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

TCTMD’s Top 10 Most Popular Stories for September 2020

Recurrent Events After MI Show Enduring Gender, Racial Gaps in Care

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Stick-on Sensor Predicts Heart-Failure Hospitalizations: Pilot Study

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content